1448347-49-6

Product Details:

CasNo： 1448347-49-6

Molecular Formula： C28H22ClF3N6O3

Purity： 99%

Synonyms: AG120; AG 120; RG120; CS-1721; RG120; EOS-60845; Ivosidenib(AG-120)
Melting point: 151-173°C
Boiling point: 854.3±65.0°C
Density: 1.51±0.1 g/cm3
Solubility: Chloroform (Slightly), Methanol (Slightly)
Pka: 11.58±0.40
Color: White to off-white
Form: Solid
Storage temp.: -20°C Freezer, Under inert atmosphere.

Description:
Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1) that specifically inhibits a mutated form of IDH1 in the cytoplasm, preventing the formation of 2-hydroxyglutarate. Ivosidenib may induce cellular differentiation as well as inhibit proliferation in IDH1-expressing tumor cells.
 

Uses:
Ivosidenib is a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers.

Definition：
Ivosidenib is a tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. It has a role as an antineoplastic agent and an EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor. It is a member of monochlorobenzenes, a cyanopyridine, a member of pyrrolidin-2-ones, an organofluorine compound, a tertiary carboxamide and a secondary carboxamide.